Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.

25 Sep 2012

Small fragments of keratin protein in the eye play a key role in warding off pathogens

When it comes to germ-busting power, the eyes have it, according to a discovery by University of California, Berkeley, researchers that could lead to new, inexpensive antimicrobial drugs.

25 Sep 2012

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that dosing with their first drug in its first Phase 1 study, was completed last week.

24 Sep 2012

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF).

24 Sep 2012

Children with mild to moderate kidney disease have carotid atherosclerosis

A federally funded study led by researchers at Johns Hopkins Children's Center has found that children with mild to moderate kidney disease have abnormally thick neck arteries, a condition known as carotid atherosclerosis, usually seen in older adults with a long history of elevated cholesterol and untreated hypertension.

21 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

Two abnormalities associated with cystic fibrosis-related diabetes

A new University of Iowa study suggests there are two root causes of a type of diabetes associated with cystic fibrosis (CF). The findings, which already have sparked a clinical trial, may guide development of new treatments or even help prevent diabetes in patients with CF.

18 Sep 2012

UCSF-led research team targets physiological factors that lead to asthma attack

A new study that identifies ways to reduce the factors that lead to an asthma attack gives hope to asthma sufferers. A UCSF researcher and his colleagues believe they have found a way to help asthma sufferers by impeding the two most significant biological responses that lead to an asthma attack.

18 Sep 2012

Parents of sickle cell babies undercounseled

Parents of newborns with the sickle cell anemia trait are significantly less likely to receive genetic counseling than those of babies who are cystic fibrosis carriers, say researchers.

17 Sep 2012

Study examines link between SES and access to lung transplantation in adult CF patients

Adult cystic fibrosis (CF) patients of low socioeconomic status (SES) have a greater chance of not being accepted for lung transplant after undergoing initial evaluation, according to a new study.

14 Sep 2012

Parents of infants with cystic fibrosis carriers more likely to receive genetic counseling

Parents of newborns with the sickle cell anemia trait were less likely to receive genetic counseling than parents whose babies are cystic fibrosis carriers, a new study from the University of Michigan shows.

12 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Each year around the world, as many as 48,000 people are diagnosed with pulmonary fibrosis and 40,000 people die – the same number of people who are lost to breast cancer annually. Pulmonary fibrosis is a devastating disease that robs people of their ability to breathe. To help raise awareness about this unknown deadly disease, the Coalition for Pulmonary Fibrosis (CPF) is kicking off "Pulmonary Fibrosis Awareness Month" this September.

10 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Study evaluates prognostic utility of novel biomarkers of cardiovascular stress

Critical Diagnostics announced today, Circulation, an American Heart Association Journal, released online the first study evaluating the power of ST2 to predict development of heart failure and other adverse outcomes in the general population titled, "Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study".

5 Sep 2012

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).

5 Sep 2012

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

InterMune, Inc. announced that new analyses of data from the RECAP extension study of Esbriet (pirfenidone) were presented today at the 2012 Annual Congress of the European Respiratory Society (ERS) in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

3 Sep 2012

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

Boehringer Ingelheim presented today for the first time data from a Phase II dose ranging study investigationg the combination of olodaterol, an investigational long-acting beta2-agonist (LABA), and tiotropium, a long-acting muscarinic antagonist (LAMA), in COPD patients, compared to the investigational agent olodaterol alone.

3 Sep 2012

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

Boehringer Ingelheim presented today the first data from the Phase III UniTinA-asthma program. In two studies, presented at the 2012 European Respiratory Society (ERS) Congress in Vienna, Austria, tiotropium delivered once daily via the Respimat inhaler significantly improved lung function and reduced asthma exacerbations in patients who remained symptomatic on current treatment with at least high dose inhaled corticosteroids (ICS) and long-acting beta agonists (LABA).

3 Sep 2012

Triple-threat approach can reduce invasive bloodstream infections in pediatric cancer patients

Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.

3 Sep 2012

Fibrosis News and Research

Further Reading

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

Small fragments of keratin protein in the eye play a key role in warding off pathogens

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Children with mild to moderate kidney disease have carotid atherosclerosis

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Two abnormalities associated with cystic fibrosis-related diabetes

UCSF-led research team targets physiological factors that lead to asthma attack

Parents of sickle cell babies undercounseled

Study examines link between SES and access to lung transplantation in adult CF patients

Parents of infants with cystic fibrosis carriers more likely to receive genetic counseling

KaloBios commences KB003 Phase 2 trial in severe asthma

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

Study evaluates prognostic utility of novel biomarkers of cardiovascular stress

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

Triple-threat approach can reduce invasive bloodstream infections in pediatric cancer patients

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News